Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service

John L Vaughn, Man-Yee Merl, Jensa C Morris, Bonnie E Gould Rothberg

Blood (2023) 142 (Supplement 1): 2335.

https://doi.org/10.1182/blood-2023-190824

Published: 2023

Journal Articles

Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT

Blood (2023) 141 (7): 713–724.

https://doi.org/10.1182/blood.2022017667

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity

Blood (2023) 141 (1): 60–71.

https://doi.org/10.1182/blood.2022015482

Published: 2023

Includes: Supplemental data

Journal Articles

Cryoglobulinemia Is More Frequently Associated with IgM Paraproteins Than Previously Reported, Interfering with Their Quantification, and Resulting in Potential Treatment Delays

Aaron Laurence Niblock, Philip Logue, Philip Windrum, Joanne Murdock, Scott Marshall McCloskey, Bridgin Merron, Suzanne McPherson, Elinor Hanna, Terence Robert Lappin, Treen C. Morris

Blood (2022) 140 (Supplement 1): 11966–11967.

https://doi.org/10.1182/blood-2022-170321

Published: 2022

Journal Articles

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study

Blood (2022) 140 (14): 1635–1649.

https://doi.org/10.1182/blood.2022015506

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome

Blood (2021) 138 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2021-147697

Published: 2021

Journal Articles

How I use allogeneic HSCT for adults with inborn errors of immunity

Siobhan O. Burns, Emma C. Morris

Blood (2021) 138 (18): 1666–1676.

https://doi.org/10.1182/blood.2020008187

Published: 2021

Includes: Supplemental data

Journal Articles

HCT for CGD? Yes, and the sooner the better

Emma C. Morris

Blood (2020) 136 (10): 1121–1123.

https://doi.org/10.1182/blood.2020007891

Published: 2020

Journal Articles

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 1367.

https://doi.org/10.1182/blood-2019-128044

Published: 2019

Journal Articles

Editing gene engineering to enhance function

Emma C. Morris

Blood (2018) 131 (3): 272–273.

https://doi.org/10.1182/blood-2017-11-816587

Published: 2018

Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD

Blood (2017) 130 (Supplement 1): 2622.

https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622

Published: 2017

Journal Articles

Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult

Blood (2017) 130 (11): 1327–1335.

https://doi.org/10.1182/blood-2017-04-777136

Published: 2017

Includes: Supplemental data

Journal Articles

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Jason B Kaplan, MD, Dale L. Bixby, MD, John C Morris, MD, Olga Frankfurt, MD, Jessica Altman, Trisha Wise-Draper, MD PhD, Patrick W. Burke, MD, Sabrina Collins, BS, Karuppiah Kannan, PhD, Ling Wang, PhD, Stephanie Faucette, PharmD, PhD, Benjamin Lee, MD PhD, Yaping Shou, MD PhD, Mark J. Levis, MD PhD, Keith W. Pratz, MD

Blood (2016) 128 (22): 2834.

https://doi.org/10.1182/blood.V128.22.2834.2834

Published: 2016

Journal Articles

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Emma C Morris, MD PhD, Thomas Andrew Fox, MRCP, Siobhan Burns, MD PhD, Ben Carpenter, MD, Kirsty J Thomson, MD, David Lowe, MD PhD, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Karl S Peggs, MD, Panagiotis Kottaridis, FRCPath, PhD MSc, Victoria Grandage, FRCPath, MRCP, PhD, Shari Denovan, RN, Sarah Grace, RN, Julia Dahlstrom, RN, Sarita Workman, RN, Andrew Symes, RN, Stephen Mackinnon, MD, Ronjon Chakraverty, BMBS, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2016) 128 (22): 4681.

https://doi.org/10.1182/blood.V128.22.4681.4681

Published: 2016

Journal Articles

Optimizing T-cell receptor gene therapy for hematologic malignancies

Emma C. Morris, Hans J. Stauss

Blood (2016) 127 (26): 3305–3311.

https://doi.org/10.1182/blood-2015-11-629071

Published: 2016

Journal Articles

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Jing Chen, Cynthia A. Pise-Masison, Joanna H. Shih, John C. Morris, John E. Janik, Kevin C. Conlon, Anne Keating, Thomas A. Waldmann

Blood (2013) 121 (11): 2029–2037.

https://doi.org/10.1182/blood-2012-05-427773

Published: 2013

Includes: Supplemental data

Journal Articles

Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

Thomas A. Waldmann, Kevin C. Conlon, Donn M. Stewart, TatYana A. Worthy, John E. Janik, Thomas A. Fleisher, Paul S. Albert, William D. Figg, Shawn D. Spencer, Mark Raffeld, Jean R. Decker, Carolyn K. Goldman, Bonita R. Bryant, Michael N. Petrus, Stephen P. Creekmore, John C. Morris

Blood (2013) 121 (3): 476–484.

https://doi.org/10.1182/blood-2012-08-450585

Published: 2013

Includes: Supplemental data

Journal Articles

Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma

Charles B. Simone, II, John C. Morris, Donn M. Stewart, Nicole E. Urquhart, John E. Janik, Robert J. Kreitman, Elena Lita, Kevin Conlon, Gilian Wharfe, Thomas A. Waldmann, Aradhana Kaushal

Blood (2012) 120 (9): 1816–1819.

https://doi.org/10.1182/blood-2012-01-401349

Published: 2012

Journal Articles

Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia

Jing Chen, Mike Petrus, Richard Bamford, Joanna H. Shih, John C. Morris, John E. Janik, Thomas A. Waldmann

Blood (2012) 119 (1): 137–143.

https://doi.org/10.1182/blood-2011-04-346759

Published: 2012

Includes: Supplemental data

Journal Articles

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Blood (2011) 118 (21): 3706.

https://doi.org/10.1182/blood.V118.21.3706.3706

Published: 2011

NARROW

Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service

Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT

Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity

Cryoglobulinemia Is More Frequently Associated with IgM Paraproteins Than Previously Reported, Interfering with Their Quantification, and Resulting in Potential Treatment Delays

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study

Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome

How I use allogeneic HSCT for adults with inborn errors of immunity

HCT for CGD? Yes, and the sooner the better

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Editing gene engineering to enhance function

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Optimizing T-cell receptor gene therapy for hematologic malignancies

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma

Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only